表紙
市場調査レポート

中国のインスリンアスパルト市場の分析

Investigation Report on China Insulin Aspart Market, 2010-2019

発行 China Research and Intelligence 商品コード 297279
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
中国のインスリンアスパルト市場の分析 Investigation Report on China Insulin Aspart Market, 2010-2019
出版日: 2015年07月24日 ページ情報: 英文 30 Pages
概要

2001年12月26日に、Novo Nordiskは世界初のインスリンアナログであるインスリンアスパルト(商品名「Novorapid」)を開発し、米国FDA(食品医薬品局)の認証を受けた、と公表しました。そして2005年4月に、はじめてのインスリンアナログ「Novomix 30」(インスリンアスパルト30%とインスリンアスパルトプロタミン70%を配合したもの)が中国でも上市されました。中国では過去30年間の急速な経済成長により食習慣やライフスタイルが激変し、肥満関連の疾患の有病者数が増加し続けています。2013年末現在、中国の糖尿病患者数は9800万〜1億2000万人に達しています。インスリンアスパルトの市場規模は、2005〜2013年の間に100倍以上も拡大し、今後も成長し続けるものと思われます。

当レポートでは、中国におけるインスリンアスパルトの市場について分析し、中国国内での生産高および病院向け売上高・価格の動向(過去5年間分)、企業別・投薬形態別の市場シェア、将来的な市場動向の見通し(今後5年間分)などを調査して、その結果を概略以下の構成でお届けします。

第1章 インスリンアスパルトの関連概念

  • 進行過程と症状
  • 世界市場での販売状況

第2章 中国のインスリンアスパルト市場の概要

  • 特許の現状
  • 主要メーカー
  • 市場規模

第3章 インスリンアスパルトの売上高の分析

  • 売上高
  • 販売量

第4章 主要メーカーの市場シェアの分析

第5章 剤形別の市場規模の分析

第6章 インスリンアスパルトの病院向け基準価格(企業別)

第7章 主要メーカーの分析

第8章 中国のインスリンアスパルト市場の将来展望

  • 市場規模の予測
  • 市場競争の予測

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 1507273

According to a report issued by WHO in 2014, the incidence of diabetes was estimated to be 9% among adults aged above 18 in the world. In 2012, diabetes reported an estimated 1.5 million cases of death, among which over 80% were in middle income and low income countries. And WHO made a prediction that diabetes will become the seventh leading cause of death by 2030. A nationwide diabetes survey carried out in 2010 in China showed that 11.6% of adults, that is 114 million people, suffered from diabetes and that the incidence of diabetes was 12.1% in men and 11% in women. And China has surpassed the US to become the country with the largest number of diabetes case.

Developed by Novo Nordisk, insulin aspart (under the trade name of Novolog) is an important drug for the treatment of diabetes. Compared with human insulin, insulin aspart, as a fast-acting insulin analog, starts working fast and reports higher peak of glucose-lowering action and lower risk of hypoglycemia. Ever since insulin aspart for injection was approved to enter China in 2012, it has been in the market for over a decade. Although the market is currently dominated by product of Novo Nordisk, some local enterprises are trying to make generic drugs. China Food and Drug Administration (CFDA) announced on its website on Jun.3, 2014 that Hisun's application to produce the APIs of insulin aspart and insulin aspart for injection through recombinant DNA technology has been accepted.

Insulin aspart develops fast after entering China. Its sales value reached CNY 336 million in 2013 and CNY 380 million in 2014 with a year-on-year increase of 13.10% while its sales volume reached 4.42 million in 2013 and 5.01 million in 2014, increasing 13.35% year on year. With economic development and lifestyle changes, the incidence of diabetes in China will keep going up, which fosters the huge demand for insulin aspart. Currently, the market is dominated by Novo Nordisk (Denmark) and Novo Nordisk (China), the former enjoying a larger market share of 100% with sales value reaching nearly CNY 380 million in 2014. As some local enterprises are trying to make generic drugs of insulin aspart, the monopoly of Novo Nordisk is expected to be broken by local products in the next few years.

Readers can get at least the following information through this report:

  • diabetes incidence in China
  • market share of insulin aspart manufacturers in sample hospitals in China
  • price of insulin aspart in Chinese hospitals
  • production of generic drugs of insulin aspart in China
  • major manufacturers of insulin aspart in China
  • share of different dosage forms of insulin aspart in Chinese hospitals
  • market outlook of insulin aspart in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-diabetic drugs
  • medical institution
  • investors/ research institutions interested in Chinese medicine market

Table of Contents

1. Related Concepts of Insulin Aspart

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Insulin Aspart in China

  • 2.1. Patent Status and Approval Information of Insulin Aspart in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Insulin Aspart Sales in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Insulin Aspart in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Insulin Aspart in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Insulin Aspart in Chinese Hospitals in 2014

7. Major Manufacturers of Insulin Aspart in Chinese Market, 2010-2014

8. Market Outlook of Insulin Aspart in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Status of Insulin Aspart in China
  • Chart Approval Information of Insulin Aspart in China
  • Chart Sales Status of Insulin Aspart in China
  • Chart Sales Value of Insulin Aspart in China, 2010-2014
  • Chart Sales Value of Insulin Aspart in Some Regions in China, 2010-2014
  • Chart Sales Volume of Insulin Aspart in China, 2010-2014
  • Chart Sales Volume of Insulin Aspart in Some Regions in China, 2010-2014
  • Chart Sales Value and Market Share of Insulin Aspart Made by Novo Nordisk (Denmark) in China, 2010-2014
  • Chart Sales Value and Market Share of Insulin Aspart Made by Novo Nordisk (China) in China, 2010-2014
  • Chart Sales Value and Market Share of Insulin Aspart Made by Novo Nordisk (US) in China, 2010-2014
  • Chart Sales Volume and Market Share of Insulin Aspart Made by Novo Nordisk (Denmark) in China, 2010-2014
  • Chart Sales Volume and Market Share of Insulin Aspart Made by Novo Nordisk (China) in China, 2010-2014
  • Chart Sales Volume and Market Share of Insulin Aspart Made by Novo Nordisk (US) in China, 2010-2014
  • Chart Price of Insulin Aspart Made by Novo Nordisk (Denmark) in Some Chinese Cities in 2014
Back to Top